{"title":"Serum asprosin, ox-LDL, and LOX-1 levels in patients with hypertension and their association with cardiovascular risk.","authors":"Çağla Özdemir, Hatice Solak","doi":"10.1080/17520363.2025.2540770","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Our study aimed to investigate the relationship between oxidized low-density lipoprotein(ox-LDL), lectin-like ox-LDL receptor-1 (LOX-1), inducible nitric oxide synthase(iNOS), endothelin 1(ET-1), and asprosin levels with cardiovascular risk.</p><p><strong>Method: </strong>The study is a case-control study. 177 patients (87 HT/90 controls) were included in the study. Biochemical parameters and blood pressure were measured. Cardiovascular risk was calculated using the European Society of Cardiology Cardiovascular Diseases (ESC CVD) risk calculator. Asprosin, oxLDL, LOX1R, ET1 and iNOS levels were measured using Enzyme-Linked ImmunoSorbent Assay (ELISA) kits in blood samples obtained after a minimum 8-hour fasting period. In statistical analyses, <i>p</i> < 0.05 was considered significant.</p><p><strong>Results: </strong>Age was significantly higher in the patient group than in the control group(<i>p</i> < .001). Following adjustment for confounding variables, including age, sex, BMI and smoking status, ANCOVA analysis revealed that ET-1 [F(1,177) = 4.002, <i>p</i> = .047, ηp<sup>2</sup> = 0.133] and oxLDL [F(1,177) = 17.221, <i>p</i> < .001, ηp<sup>2</sup> = 0.262] levels were elevated in the control group relative to the HT group. The correlation analysis revealed a positive correlation between age and cardiovascular risk (<i>p</i> < .001). Furthermore, a negative correlation was identified between cardiovascular risk and ET1 (<i>p</i> < .05), iNOS (<i>p</i> < .001), asprosin (<i>p</i> < .05) and oxLDL ;(<i>p</i> < .001).</p><p><strong>Conclusion: </strong>ET1 and ox-LDL were lower in the HT group treated with antihypertensive therapy compared to the control group. Moreover, asprosin was found to be low in patients with high cardiovascular risk.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"637-645"},"PeriodicalIF":2.1000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344817/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2540770","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: Our study aimed to investigate the relationship between oxidized low-density lipoprotein(ox-LDL), lectin-like ox-LDL receptor-1 (LOX-1), inducible nitric oxide synthase(iNOS), endothelin 1(ET-1), and asprosin levels with cardiovascular risk.
Method: The study is a case-control study. 177 patients (87 HT/90 controls) were included in the study. Biochemical parameters and blood pressure were measured. Cardiovascular risk was calculated using the European Society of Cardiology Cardiovascular Diseases (ESC CVD) risk calculator. Asprosin, oxLDL, LOX1R, ET1 and iNOS levels were measured using Enzyme-Linked ImmunoSorbent Assay (ELISA) kits in blood samples obtained after a minimum 8-hour fasting period. In statistical analyses, p < 0.05 was considered significant.
Results: Age was significantly higher in the patient group than in the control group(p < .001). Following adjustment for confounding variables, including age, sex, BMI and smoking status, ANCOVA analysis revealed that ET-1 [F(1,177) = 4.002, p = .047, ηp2 = 0.133] and oxLDL [F(1,177) = 17.221, p < .001, ηp2 = 0.262] levels were elevated in the control group relative to the HT group. The correlation analysis revealed a positive correlation between age and cardiovascular risk (p < .001). Furthermore, a negative correlation was identified between cardiovascular risk and ET1 (p < .05), iNOS (p < .001), asprosin (p < .05) and oxLDL ;(p < .001).
Conclusion: ET1 and ox-LDL were lower in the HT group treated with antihypertensive therapy compared to the control group. Moreover, asprosin was found to be low in patients with high cardiovascular risk.
目的：探讨氧化低密度脂蛋白（ox-LDL）、凝集素样ox-LDL受体-1 （LOX-1）、诱导型一氧化氮合酶（iNOS）、内皮素1（ET-1）和阿斯利尿素水平与心血管疾病的关系。方法：本研究为病例对照研究。177例患者（87例HT/90例对照）纳入研究。测量生化指标和血压。使用欧洲心血管病学会（ESC CVD）风险计算器计算心血管风险。禁食至少8小时后，采用酶联免疫吸附试验（ELISA）试剂盒检测血样品中的Asprosin、oxLDL、LOX1R、ET1和iNOS水平。结果：患者组年龄明显高于对照组(p p =。[047, ηp2 = 0.133]和oxLDL [F(1,177) = 17.221, p2 = 0.262]水平均高于HT组。相关分析显示年龄与心血管风险呈正相关（p p p p p p）结论：HT组降压治疗后ET1和ox-LDL低于对照组。此外，asprosin在心血管风险高的患者中含量较低。
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
